Efficacy of human Lyme disease vaccine formulations in a mouse model.
Efficacy of human Lyme disease vaccine formulations in a mouse model.
复制标题
人类莱姆病疫苗制剂在小鼠模型中的功效。
DOI：
10.1093/infdis/171.5.1368
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Fikrig,E
中科院分区：
文献类型：
--
作者：
Telford3rd,SR;Kantor,FS;Lobet,Y;Barthold,SW;Spielman,A;Flavell,RA;Fikrig,E
虽然重组外表面蛋白A （OspA）免疫似乎可以保护小鼠免受莱姆病病原体的感染，但所有报道的实验都涉及不适合用于人类或未使用现实挑战的配方。本研究旨在确定制备和用于I期人体试验的疫苗，包括目前在地方性伯氏疏螺旋体地区用于II期试验的疫苗，是否在C3H/HeJ小鼠模型中具有保护作用。挑战是从试验的一个主要地点收集的蜱虫。接种疫苗的小鼠没有被感染或发病，而未接种疫苗的小鼠有60%被感染。螺旋体在几乎所有恢复的攻击蜱的肠道内被摧毁。这些重组OspA制剂可以有效地诱导免疫，保护从野外试验点收集的蜱虫叮咬的小鼠免受莱姆病的侵害。
Although immunization with recombinant outer surface protein A (OspA) appears to protect mice against infection by the agent of Lyme disease, all reported experiments have involved formulations that would not be suitable for use in humans or have not used realistic challenges. This study was designed to determine whether vaccines prepared and used in a phase I human trial, including one currently being used for a phase II trial in sites with endemicBorrelia burgdorferi, conferred protection in the C3H/HeJ mouse model. The challenge was ticks collected from a major site of the trial. None of the vaccinated mice became infected or developed disease, whereas 60% of unvaccinated mice became infected. Spirochetes were destroyed within the guts of virtually all recovered challenge ticks. These preparations of recombinant OspA effectively induced immunity to protect mice from Lyme disease when bitten by ticks collected from a field trial site.